2024
Peri-Transplant Inflammation and Long-Term Diabetes Outcomes Were Not Impacted by Either Etanercept or Alpha-1-Antitrypsin Treatment in Islet Autotransplant Recipients
Abdel-Karim T, Hodges J, Herold K, Pruett T, Ramanathan K, Hering B, Dunn T, Kirchner V, Beilman G, Bellin M. Peri-Transplant Inflammation and Long-Term Diabetes Outcomes Were Not Impacted by Either Etanercept or Alpha-1-Antitrypsin Treatment in Islet Autotransplant Recipients. Transplant International 2024, 37: 12320. PMID: 38357216, PMCID: PMC10864605, DOI: 10.3389/ti.2024.12320.Peer-Reviewed Original ResearchConceptsAlpha 1-antitrypsinTolerance testPerioperative periodAlpha-1 antitrypsin treatmentMixed meal tolerance testBenefit of etanerceptMeal tolerance testTrial of etanerceptGlucose tolerance testMonths post-TPIATIntravenous glucose tolerance testIslet autotransplant recipientsLong-term diabetes outcomesSerum A1ATEtanercept groupAdministered etanerceptAutotransplant recipientsDiabetes outcomesInflammatory profileEtanerceptIL-10Endogenous upregulationMCP-1Randomized trialsInflammatory cytokines
2018
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, Gettinger S, Sznol M, Young A, Rushakoff R, Lee J, Bluestone JA, Anderson M, Herold KC. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors. Diabetes 2018, 67: dbi180002. PMID: 29937434, PMCID: PMC6054443, DOI: 10.2337/dbi18-0002.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Agents, ImmunologicalAutoimmune DiseasesB7-H1 AntigenDiabetes Mellitus, Type 1Genetic Predisposition to DiseaseGenotypeHLA-DR4 AntigenHumansHypoglycemic AgentsInsulinInsulin SecretionIsoantibodiesKetosisModels, ImmunologicalNeoplasmsPancreasPancreatitisProgrammed Cell Death 1 ReceptorConceptsInsulin-dependent diabetesCheckpoint inhibitorsAdverse eventsHLA-DR4Classic type 1 diabetesPD-L1 checkpoint inhibitorsEvidence of pancreatitisImmune adverse eventsSolid organ cancersType 1 diabetesPeridiagnosis periodPositive autoantibodiesL1 antibodyInsulin-DependentHigh riskPatientsDiabetesCancerInhibitorsKetoacidosisAutoimmuneAutoantibodiesPancreatitisComplicationsSyndrome
2015
β Cell death and dysfunction during type 1 diabetes development in at-risk individuals
Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, Ledizet M, Sosenko JM, Krischer JP, Palmer JP. β Cell death and dysfunction during type 1 diabetes development in at-risk individuals. Journal Of Clinical Investigation 2015, 125: 1163-1173. PMID: 25642774, PMCID: PMC4362259, DOI: 10.1172/jci78142.Peer-Reviewed Original ResearchConceptsUnmethylated INS DNAINS DNARisk individualsType 1 diabetes developmentCell killingT1D-associated autoimmunityUnmethylated insulin DNADiagnosis of T1DHigh-risk subjectsAmerican Diabetes AssociationHealthy control subjectsJuvenile Diabetes Research FoundationPrimary pathologic processType 1 diabetesCell deathΒ-cell deathNonprogressor groupPeridiagnosis periodTrialNet PathwayBlood testsDiabetes AssociationDiabetes developmentIslet autotransplantMetabolic decompensationControl subjects